• Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • DCprime Merger Information
    • Overview
    • Media
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
    • Expanded Access / Compassionate Use Policy
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsPress ReleasesPressreleases 2017

Investors

  • Overview
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads

Press releases 2017

  • All
  • Regulatory release

Immunicum AB (publ) Announces the Outcome of the Rights Issue

29 December 2017 Read more R

Immunicum AB Publishes Prospectus in Connection with Rights Issue and Listing on Nasdaq Stockholm

5 December 2017 Read more R

Immunicum Announces Report from the Extraordinary General Meeting on December 4, 2017

4 December 2017 Read more R

Immunicum Announces Positive Preliminary Results from Proof-of-Concept Animal Study Testing Combination of Ilixadencel and Checkpoint Inhibitors

27 November 2017 Read more R

Nasdaq Stockholm's Listing Committee Has Approved Immunicum's Shares for Listing on Nasdaq Stockholm Conditional Upon Completion of the Rights Issue

24 November 2017 Read more R

Immunicum AB: Invitation to Investor Events

22 November 2017 Read more

Immunicum AB (publ): Interim Report Q3 - Corporate Update and Outlook

17 November 2017 Read more R

Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology

10 November 2017 Read more

Immunicum AB (publ) Presents Further Preclinical Ilixadencel Mode of Action Data at Annual SITC Meeting

7 November 2017 Read more

Notice to Attend the Extraordinary General Meeting of Immunicum

2 November 2017 Read more R

The Board of Directors of Immunicum AB (publ) Resolves on a 90% Secured Rights Issue of up to SEK 223 Million to Finance Further Development of its Portfolio

2 November 2017 Read more R

Immunicum AB (publ) Announces Appointment of Sharon Longhurst as Head of CMC

10 October 2017 Read more

Immunicum AB (publ) Announces the Nomination Committee for AGM 2018

9 October 2017 Read more

Immunicum AB (publ) Announces Completion of HCC Phase I/II Clinical Study

28 September 2017 Read more R

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US

21 September 2017 Read more

Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September

22 August 2017 Read more

Immunicum AB (publ): Interim Report Q2 - Corporate Update and Outlook

18 August 2017 Read more R

Immunicum AB (publ) Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel

17 August 2017 Read more R

Immunicum AB (publ) Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study

15 August 2017 Read more

Immunicum AB (publ) Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel

10 August 2017 Read more

Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma

20 June 2017 Read more R

Immunicum AB (publ) Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX®

12 June 2017 Read more

Immunicum AB (publ) Announces Participation at Conferences in June

30 May 2017 Read more

Immunicum AB: Quarterly Report January-March 2017

19 May 2017 Read more R

Report from the Annual General Meeting of Immunicum AB (publ) on April 26, 2017

26 April 2017 Read more R

Kommuniké från årsstämma i Immunicum AB (publ) den 26 april 2017

26 April 2017 Read more R

Immunicum AB (publ) Announces Upcoming Presentations at Conferences in May

24 April 2017 Read more

Immunicum AB (publ) Announces Annual General Meeting of Shareholders

27 March 2017 Read more R

Immunicum's uplisting to Nasdaq Stockholm postponed

24 March 2017 Read more R

Immunicum AB Publishes the Annual Report for 2016

17 March 2017 Read more R

Immunicum AB Announces Enrollment of First Patient in Phase I/II GIST Trial Following Study Protocol Amendment

7 March 2017 Read more R

Immunicum AB Appoints Sijme Zeilemaker as Senior Director Business Development

2 March 2017 Read more R

Immunicum AB Announces Presentations and Participations at Upcoming Conferences in March

1 March 2017 Read more

Immunicum AB: Year-End Report 2016 (July 2016 - December 2016)

17 February 2017 Read more R

Immunicum AB announces approval in France for its Clinical Trial Application for INTUVAX in metastatic renal cell carcinoma

14 February 2017 Read more R

Immunicum AB Appoints Karin Hoogendoorn as Head of CMC

13 February 2017 Read more R

Immunicum Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Webcast

9 February 2017 Read more R

Immunicum AB CEO to present at BIO CEO & Investor Conference

3 February 2017 Read more

Immunicum AB (publ) Announces the Outcome of the Rights Issue

29 December 2017 Read more R

Immunicum AB Publishes Prospectus in Connection with Rights Issue and Listing on Nasdaq Stockholm

5 December 2017 Read more R

Immunicum Announces Report from the Extraordinary General Meeting on December 4, 2017

4 December 2017 Read more R

Immunicum Announces Positive Preliminary Results from Proof-of-Concept Animal Study Testing Combination of Ilixadencel and Checkpoint Inhibitors

27 November 2017 Read more R

Nasdaq Stockholm's Listing Committee Has Approved Immunicum's Shares for Listing on Nasdaq Stockholm Conditional Upon Completion of the Rights Issue

24 November 2017 Read more R

Immunicum AB (publ): Interim Report Q3 - Corporate Update and Outlook

17 November 2017 Read more R

Notice to Attend the Extraordinary General Meeting of Immunicum

2 November 2017 Read more R

The Board of Directors of Immunicum AB (publ) Resolves on a 90% Secured Rights Issue of up to SEK 223 Million to Finance Further Development of its Portfolio

2 November 2017 Read more R

Immunicum AB (publ) Announces Completion of HCC Phase I/II Clinical Study

28 September 2017 Read more R

Immunicum AB (publ): Interim Report Q2 - Corporate Update and Outlook

18 August 2017 Read more R

Immunicum AB (publ) Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel

17 August 2017 Read more R

Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma

20 June 2017 Read more R

Immunicum AB: Quarterly Report January-March 2017

19 May 2017 Read more R

Report from the Annual General Meeting of Immunicum AB (publ) on April 26, 2017

26 April 2017 Read more R

Kommuniké från årsstämma i Immunicum AB (publ) den 26 april 2017

26 April 2017 Read more R

Immunicum AB (publ) Announces Annual General Meeting of Shareholders

27 March 2017 Read more R

Immunicum's uplisting to Nasdaq Stockholm postponed

24 March 2017 Read more R

Immunicum AB Publishes the Annual Report for 2016

17 March 2017 Read more R

Immunicum AB Announces Enrollment of First Patient in Phase I/II GIST Trial Following Study Protocol Amendment

7 March 2017 Read more R

Immunicum AB Appoints Sijme Zeilemaker as Senior Director Business Development

2 March 2017 Read more R

Immunicum AB: Year-End Report 2016 (July 2016 - December 2016)

17 February 2017 Read more R

Immunicum AB announces approval in France for its Clinical Trial Application for INTUVAX in metastatic renal cell carcinoma

14 February 2017 Read more R

Immunicum AB Appoints Karin Hoogendoorn as Head of CMC

13 February 2017 Read more R

Immunicum Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Webcast

9 February 2017 Read more R
Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 (0)8 732 8400

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2021 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve